Oncology Institute, Inc. (TOI) Stock Price & Analysis

Oncology Institute, Inc. (TOI) fell 1.78% to USD 4.98 as of July 25, 2026 at 22:03 UTC, according to Nexqual real-time market data.

TOI last closed at USD 5.07; the session ranged USD 4.97–5.17 on volume of 1,143,202 shares. Market capitalization is $497.92M, with a 52-week range of USD 2.32–6.67 (NCM). Source: Nexqual, July 25, 2026 at 22:03 UTC.

Key Statistics (as of July 25, 2026 at 22:03 UTC)

PriceUSD 4.98
Change▼ 1.78% (down)
Previous CloseUSD 5.07
OpenUSD 5.09
Day RangeUSD 4.97 – 5.17
52-Week RangeUSD 2.32 – 6.67
Volume1,143,202 shares
Market Cap$497.92M
ExchangeNCM

Technical Analysis (TOI)

Nexqual's technical model rates TOI "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 22:03 UTC.

Overall SignalSELL
RSI (14)42.47 (neutral)
vs SMA50Below (USD 5.05)
MACD0.04 (positive)

Analyst Ratings (TOI)

Wall Street analysts rate TOI "None" based on 5 analysts, with a mean price target of USD 8.4 (range USD 7–10), per Nexqual as of July 25, 2026 at 22:03 UTC.

Consensus RatingNone
Analyst Count5
Mean TargetUSD 8.4
High TargetUSD 10
Low TargetUSD 7
Buy / Hold / Sell5 / 0 / 0

Earnings (TOI)

Next Earnings Date2026-08-10
Revenue Estimate$155.20M

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -0.02 vs est -0.09 ▲ beat
2025-12-31USD -0.06 vs est -0.09 ▲ beat
2025-09-30USD -0.14 vs est -0.11 ▼ miss
2025-06-30USD -0.15 vs est -0.12 ▼ miss

Source: Nexqual, July 25, 2026 at 22:03 UTC.

Financials & Fundamentals (TOI)

Total Revenue$545.76M
Revenue Growth (YoY)+41.20%
Gross Margin+15.12%
Operating Margin-4.42%
Profit Margin-7.97%
Current Ratio1.47
Total Cash$30.28M
Total Debt$104.91M
Free Cash Flow$-15.31M

Source: Nexqual, July 25, 2026 at 22:03 UTC.

Financial Health Score (TOI)

Nexqual rates Oncology Institute, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 22:03 UTC.

GrowthStrong — Revenue +41% YoY (latest Q)
ProfitabilityWeak — Gross margin 15%, operating -4%
Balance SheetMixed — $30M cash vs $105M debt
Cash FlowWeak — FCF negative: -$15M, burning cash
EfficiencyMixed — No data

Ownership (TOI)

Insider Ownership+18.22%
Institutional Ownership+45.77%
Shares Outstanding99.98M
Float87.24M
Short % of Float+8.30%

Source: Nexqual, July 25, 2026 at 22:03 UTC.

Leadership (TOI)

Oncology Institute, Inc. is led by Daniel Virnich FACHE (age 46), CEO & Executive Director, per Nexqual as of July 25, 2026 at 22:03 UTC.

CEO & Executive DirectorDaniel Virnich FACHE (age 46)
Chief Financial OfficerRobert Carter (age 39)
Senior Vice President of FinanceStephen Cella

Major Backers & Investors (TOI)

Notable institutional backers of Oncology Institute, Inc. include Deerfield Management Company, L.P, Kanen Wealth Management LLC, Josh Arnold Investment Consultant, Llc, according to Nexqual as of July 25, 2026 at 22:03 UTC.

Active Investors

InvestorStake
Deerfield Management Company, L.P3.36%
Kanen Wealth Management LLC2.78%
Josh Arnold Investment Consultant, Llc2.46%
Balyasny Asset Management LP1.83%
Wexford Capital LP1.71%
CenterBook Partners LP1.57%

Index Funds (Passive)

FundStake
Vanguard Group7.6%
BlackRock6.98%
Geode Capital1.76%
State Street1.46%

Source: Nexqual, July 25, 2026 at 22:03 UTC.

From Oncology Institute, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
XLOXilio Therapeutics, Inc.USD 8.65▲ 2%
BBLGBone Biologics CorpUSD 1.07▼ 2.73%
ICUSeaStar Medical Holding CorporaUSD 3.75▼ 3.6%
NMADNomad Power Solutions, Inc.USD 4.84▼ 3.01%
SABSSAB Biotherapeutics, Inc.USD 3.51▼ 1.96%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 22:03 UTC. This page is informational and not investment advice.